US2023313126A1PendingUtilityA1
Peptide Conjugated Hydrogel Substrate for the Maintenance and Expansion of Human Pluripotent Stem Cells
Assignee: UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATIONPriority: Dec 16, 2016Filed: Feb 2, 2023Published: Oct 5, 2023
Est. expiryDec 16, 2036(~10.4 yrs left)· nominal 20-yr term from priority
C12N 5/0068C12N 5/0018C07K 14/00C07K 7/04C07K 14/705C12N 5/0606C12N 5/0012C07K 17/10C12N 2513/00C12N 2533/74C12N 2537/10
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions useful for propagation of pluripotent stem cells are provided. The compositions comprise a polysaccharide hydrogel linked to a peptide fragment of the extracellular domain of epithelial cadherin. Methods of making the composition, and culturing pluripotent stem cells also are provided.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A composition comprising at least one pluripotent stem cell encapsulated within a three-dimensional biocompatible hydrogel linked to a polypeptide comprising a cell-binding sequence of an epithelial cadherin extracellular domain.
2 . The composition of claim 1 , wherein the hydrogel is a synthetic or naturally derived polysaccharide hydrogel.
3 . The composition of claim 2 , wherein the polysaccharide is a carboxylated polysaccharide.
4 . The composition of claim 2 , wherein the polysaccharide hydrogel is alginate.
5 . The composition of claim 1 , wherein the pluripotent stem cell is an induced pluripotent stem cell or an embryonic stem cell and/or is a human pluripotent stem cell.
6 . The composition of claim 1 , wherein the polypeptide comprises:
the sequence LFSHAVSSNG (SEQ ID NO: 2), SHAVSS (SEQ ID NO: 3), QGADTPPVGV (SEQ ID NO: 4), and/or ADTPPV (SEQ ID NO: 5); a sequence comprising the amino acid sequence HAV and/or ADT; a sequence having at least five consecutive amino acids of SHAVSS (SEQ ID NO: 3) and/or ADTPPV (SEQ ID NO: 5); or a sequence having at least 80% sequence identity with SHAVSS (SEQ ID NO: 3) and ADTPPV (SEQ ID NO: 5).
7 . The composition of claim 1 , wherein the polypeptide is chosen from:
(HAV10, SEQ ID NO: 2)
LFSHAVSSNG;
(HAV6, SEQ ID NO: 3)
SHAVSS;
(ADT10, SEQ ID NO: 4)
QGADTPPVGV,
and
(ADT6, SEQ ID NO: 5)
ADTPPV.
8 . The composition of claim 1 , wherein the polypeptide is linked directly to the hydrogel by an amide bond.
9 . The composition of claim 1 , wherein the hydrogel comprises pendant free carboxyl groups, wherein 99% or less, 95% or less, 90% or less, 80% or less, 75% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 25% or less, 20% or less, 10% or less, 5% or less, or 1% or less of monomers of the hydrogel have the peptide linked thereto.
10 . The composition of claim 1 , wherein the composition is anionic and is in the form of capsules formed with a divalent cation.
11 . A method of preparing an encapsulated pluripotent stem cell, comprising:
mixing one or more pluripotent stem cells with a hydrogel monomer to form a first mixture, wherein the hydrogel monomer is linked to a polypeptide comprising a cell-binding sequence of an epithelial cadherin extracellular domain; and adding a divalent cation to the mixture or adding the mixture to a divalent cation, thereby encapsulating the one or more pluripotent stem cells in a three-dimensional hydrogel.
12 . The method of claim 11 , wherein the divalent cation is calcium chloride or barium chloride.
13 . The method of claim 11 , wherein the pluripotent stem cells are induced pluripotent stem cells.
14 . The method of claim 13 , wherein the pluripotent stem cells are human.
15 . The method of claim 11 , wherein the polypeptide is linked directly to the hydrogel monomer by an amide bond.
16 . The method of claim 11 , wherein the hydrogel monomer comprises a polysaccharide.
17 . The method of claim 11 , wherein the hydrogel monomer is a synthetic or naturally derived monomer.
18 . The method of claim 11 , wherein the hydrogel monomer comprises alginate.
19 . The method of claim 11 , wherein the polypeptide comprising a cell-binding sequence of an epithelial cadherin extracellular domain comprises:
the sequence LFSHAVSSNG (SEQ ID NO: 2), SHAVSS (SEQ ID NO: 3), QGADTPPVGV (SEQ ID NO: 4), and/or ADTPPV (SEQ ID NO: 5); a sequence comprising the amino acid sequence HAV and/or ADT; a sequence having at least five consecutive amino acids of SHAVSS (SEQ ID NO: 3) and/or ADTPPV (SEQ ID NO: 5); or a sequence having at least 80% sequence identity with SHAVSS (SEQ ID NO: 3) and ADTPPV (SEQ ID NO: 5).
20 . The method of claim 11 , wherein the polypeptide is chosen from:
(HAV10, SEQ ID NO: 2)
LFSHAVSSNG;
(HAV6, SEQ ID NO: 3)
SHAVSS;
(ADT10, SEQ ID NO: 4)
QGADTPPVGV,
and
(ADT6, SEQ ID NO: 5)
ADTPPV.Join the waitlist — get patent alerts
Track US2023313126A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.